Compounds > levofloxacin
Page last updated: 2024-09-04

levofloxacin and bortezomib

levofloxacin has been researched along with bortezomib in 5 studies

Compound Research Comparison

Studies
(levofloxacin)		Trials
(levofloxacin)		Recent Studies (post-2010)
(levofloxacin)		Studies
(bortezomib)		Trials
(bortezomib)		Recent Studies (post-2010) (bortezomib)
4,3465812,2096,8688604,753

Protein Interaction Comparison

ProteinTaxonomylevofloxacin (IC50)bortezomib (IC50)
Proteasome subunit beta type-11Homo sapiens (human)0.3213
26S proteasome non-ATPase regulatory subunit 11Homo sapiens (human)0.5335
26S proteasome non-ATPase regulatory subunit 12Homo sapiens (human)0.5335
26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)0.5335
Proteasome subunit alpha type-7Homo sapiens (human)0.3213
Histone deacetylase 3Homo sapiens (human)1.18
26S proteasome non-ATPase regulatory subunit 3Homo sapiens (human)0.5335
Cathepsin GHomo sapiens (human)1.81
Lysosomal protective proteinHomo sapiens (human)9.2
26S proteasome regulatory subunit 6AHomo sapiens (human)0.5335
Nuclear factor NF-kappa-B p105 subunitHomo sapiens (human)0.085
Proteasome subunit beta type-1Homo sapiens (human)0.2149
ChymaseHomo sapiens (human)1.19
Proteasome subunit alpha type-1Homo sapiens (human)0.3213
Proteasome subunit alpha type-2Homo sapiens (human)0.3213
Proteasome subunit alpha type-3Homo sapiens (human)0.3213
Proteasome subunit alpha type-4Homo sapiens (human)0.3213
Proteasome subunit beta type-8Homo sapiens (human)0.1681
Proteasome subunit beta type-8Mus musculus (house mouse)0.0168
Proteasome subunit beta type-9Homo sapiens (human)0.2059
Proteasome subunit alpha type-5Homo sapiens (human)0.3213
Proteasome subunit beta type-4Homo sapiens (human)0.3213
Proteasome subunit beta type-6Homo sapiens (human)0.2842
Proteasome subunit beta type-5Homo sapiens (human)0.1407
26S proteasome regulatory subunit 7Homo sapiens (human)0.5335
Lon protease homolog, mitochondrialHomo sapiens (human)0.183
Proteasome subunit beta type-10Homo sapiens (human)0.5359
26S proteasome regulatory subunit 6BHomo sapiens (human)0.5335
26S proteasome non-ATPase regulatory subunit 8Homo sapiens (human)0.5335
Proteasome subunit beta type-3Homo sapiens (human)0.3213
Proteasome subunit beta type-2Homo sapiens (human)0.9297
26S proteasome non-ATPase regulatory subunit 7Homo sapiens (human)0.5335
26S proteasome non-ATPase regulatory subunit 4Homo sapiens (human)0.5335
26S proteasome complex subunit SEM1Homo sapiens (human)0.5335
Proteasome subunit alpha type-6Homo sapiens (human)0.3213
26S proteasome regulatory subunit 4Homo sapiens (human)0.5335
26S proteasome regulatory subunit 8Homo sapiens (human)0.5335
26S proteasome regulatory subunit 10BHomo sapiens (human)0.5335
Nuclear factor NF-kappa-B p100 subunit Homo sapiens (human)0.085
Transcription factor p65Homo sapiens (human)0.085
26S proteasome non-ATPase regulatory subunit 2Homo sapiens (human)0.5335
Histone deacetylase 1Homo sapiens (human)0.62
26S proteasome non-ATPase regulatory subunit 6Homo sapiens (human)0.5335
Proteasomal ubiquitin receptor ADRM1Homo sapiens (human)0.5335
ATP-dependent Clp protease proteolytic subunitStaphylococcus aureus subsp. aureus NCTC 83255.3
NACHT, LRR and PYD domains-containing protein 3 Mus musculus (house mouse)0.0407
Proteasome subunit alpha-type 8Homo sapiens (human)0.3213
Histone deacetylase 2Homo sapiens (human)0.8
Proteasome subunit beta type-7Homo sapiens (human)0.3213
26S proteasome non-ATPase regulatory subunit 1Homo sapiens (human)0.5335
Histone deacetylase 8Homo sapiens (human)0.072
26S proteasome non-ATPase regulatory subunit 13Homo sapiens (human)0.5335

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's4 (80.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lombardo, F; Obach, RS; Waters, NJ1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Ahn, JS; Jang, HC; Jung, SH; Kang, SJ; Kim, HJ; Kim, YK; Lee, JJ; Lee, SS; Yang, DH1

Reviews

1 review(s) available for levofloxacin and bortezomib

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

4 other study(ies) available for levofloxacin and bortezomib

ArticleYear
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Effect of levofloxacin prophylaxis for prevention of severe infections in multiple myeloma patients receiving bortezomib-containing regimens.
    International journal of hematology, 2014, Volume: 100, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Comorbidity; Female; Humans; Incidence; Infections; Levofloxacin; Male; Middle Aged; Multiple Myeloma; Pyrazines; Treatment Outcome

2014